Evidence map›Paper›PMID 36925921›Full record

ArticleFrontiers in oncology2023

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy.

Dongxian Jiang, Qi Song, Han Tang, Peng Shi, Xiaolei Zhang, Yufeng Liu, Haixing Wang, Minying Deng, Jie Huang, Jieakesu Su and 3 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Dongxian JiangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Qi SongDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Han TangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Peng ShiCenter for Evidence-based Medicine, Fudan University, Shanghai, China.
Xiaolei ZhangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yufeng LiuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Haixing WangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Minying DengDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jie HuangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jieakesu SuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lijie TanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: The distribution of residual esophageal squamous cell carcinoma (ESCC) in the esophageal wall and resected lymph nodes was evaluated after neoadjuvant chemoimmunotherapy (nICT). Methods and results: Clinical data were collected from 137 ESCC patients who underwent anti-programmed death 1 therapy and esophagectomy. Ninety (65.7%) achieved an major pathological response (MPR) in the esophageal wall, and 27 (19.7%) achieved an MPR in the lymph nodes. Pathologically complete response (pCR, ypT0N0) was observed in 26 patients (19%). Residual tumors located in the mucosa and/or submucosa were found in 94.6% of nonpCR patients. In the minor responders, 97.8% had residual tumor >10% in the mucosa or submucosa. A preferential regression direction toward the lumen was found in 76.4% of prepT2 nonpCR patients, or 60.7% of prepT3-4a nonpCR patients. The correlation between pCR in the esophageal wall and in lymph nodes was not significant ( Conclusions: After nICT for ESCC, residual tumors were frequently found in the mucosa or submucosa, with relatively high responsiveness of the invasive front and a significant correlation with downstaging, which may help clinicians make appropriate decisions about postoperative treatment and surveillance. The differences in pCR status in primary tumors, resected lymph nodes, and RLN lymph nodes indicated the importance of assessing regression changes in all resected lymph nodes during clinical practice.

Indexed as

anti-PD-1 therapydistributionesophageal squamous cell carcinomapathological responseresidual tumor

Identifiers

PMID36925921
PMCPMC10012861
OpenAlexW4322627411

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read223
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.